Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors

BMC Pharmacology

Volumn 11, Issue , 2011, Pages

  Hayase, Tamaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ANTIDEPRESSANT AGENT; ARVANIL; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; DOPAMINE DERIVATIVE; N ARACHIDONYLDOPAMINE; NICOTINE; OLVANIL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; AMIDE; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL DOPAMINE; DOPAMINE; DRUG DERIVATIVE; LIGAND; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; IMMOBILIZATION STRESS; MALE; MOUSE; NONHUMAN; SWIMMING; TOBACCO DEPENDENCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; IMMOBILIZATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARACHIDONIC ACIDS; CAPSAICIN; DEPRESSION; DOPAMINE; HINDLIMB SUSPENSION; LIGANDS; MALE; MICE; MICE, INBRED ICR; NICOTINE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STRESS, PSYCHOLOGICAL; SWIMMING; TRPV CATION CHANNELS;

EID: 79960562968     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-11-6     Document Type: Article

References (59)

1. Osaki Y, Tanihata T, Ohida T, Minowa M, Wada K, Suzuki K, Kaetsu A, Okamoto M, Kishimoto T. Adolescent smoking behaviour and cigarette brand preference in Japan. Tob Control 2006, 15:172-180. 10.1136/tc.2005.013060, 2564654, 16728747.
2. Zarocostas J. WHO report warns deaths from tobacco could rise beyond eight million a year by 2030. BMJ 2008, 336:299. 2234514, 18258963.
3. Warren CW, Lea V, Lee J, Jones NR, Asma S, McKenna M. Change in tobacco use among 13-15 year olds between 1999 and 2008: findings from the Global Youth Tobacco Survey. Glob Health Promot 2009, 16(Suppl 2):38-90.
4. Picciotto MR. Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998, 51:165-172. 10.1016/S0376-8716(98)00074-X, 9716938.
5. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106. 10.1097/00001756-200207020-00006, 12151749.
6. West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989, 19:981-985. 10.1017/S0033291700005705, 2594893.
7. Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D, Caporaso N. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 1996, 21:9-19. 10.1016/0306-4603(95)00032-1, 8729703.
8. Parrott AC. Heightened stress and depression follow cigarette smoking. Psychol Rep 2004, 94:33-34. 10.2466/pr0.94.1.33-34, 15077744.
9. Hayase T. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs. BMC Neurosci 2007, 8:76. 10.1186/1471-2202-8-76, 2075518, 17877812.
10. Hayase T. Nicotine (NC)-induced "depressive" behavioral symptoms and effects of antidepressants including cannabinoids (CBs). J Toxicol Sci 2008, 33:555-564. 10.2131/jts.33.555, 19043277.
11. Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry 1996, 57:387-389.
12. Parrott AC. Cigarette-derived nicotine is not a medicine. World J Biol Psychiatry 2003, 4:49-55. 10.3109/15622970309167951, 12692774.
13. Mannucci C, Tedesco M, Bellomo M, Caputi AP, Calapai G. Long-term effects of nicotine on the forced swimming test in mice: an experimental model for the study of depression caused by smoke. Neurochem Int 2006, 49:481-486. 10.1016/j.neuint.2006.03.010, 16697079.
14. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732. 10.1038/266730a0, 559941.
15. Armario A, Gil M, Marti J, Pol O, Balasch J. Influence of various acute stressors on the activity of adult male rats in a holeboard and in the forced swim test. Pharmacol Biochem Behav 1991, 39:373-377. 10.1016/0091-3057(91)90194-7, 1946578.
16. Hayase T, Yamamoto Y, Yamamoto K. Stress-related behavioral alterations accompanying cocaine toxicity: the effects of mixed opioid drugs. Nihon Arukoru Yakubutsu Igakkai Zasshi 2000, 35:402-414.
17. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 1999, 72:1117-1124.
18. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002, 7:525-535. 10.1038/sj.mp.4001035, 12140772.
19. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
20. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809. 10.1126/science.1083328, 12907793.
21. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115:3104-3116. 10.1172/JCI25509, 1253627, 16224541.
22. Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LA. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 2006, 24:1845-1849. 10.1111/j.1460-9568.2006.05061.x, 17067290.
23. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002, 954:73-81. 10.1016/S0006-8993(02)03344-9, 12393235.
24. Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867. 10.1016/S0028-3908(02)00118-1, 12384171.
25. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000, 97:3655-3660. 10.1073/pnas.060496197, 16295, 10725386.
26. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002, 99:8400-8405. 10.1073/pnas.122196999, 123079, 12060783.
27. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 2004, 1007:152-159. 10.1016/j.brainres.2004.02.016, 15064146.
28. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139:1405-1415. 10.1016/j.neuroscience.2006.02.074, 16603318.
29. Kasckow JW, Mulchahey JJ, Geracioti TD. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:291-295. 10.1016/j.pnpbp.2003.10.007, 14751425.
30. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007, 114:13-33. 10.1016/j.pharmthera.2007.01.005, 17349697.
31. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008, 14:42-54. 10.2174/138161208783330790, 18220817.
32. Roberts RG, Stevenson JE, Westerman RA, Pennefather J. Nicotinic acetylcholine receptors on capsaicin-sensitive nerves. Neuroreport 1995, 6:1578-1582. 10.1097/00001756-199507310-00028, 7579153.
33. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz JJ. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001, 420:123-131. 10.1016/S0014-2999(01)01012-3, 11408034.
34. Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. N-acyl-dopamines: novel synthetic CB (1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, 351:817-824. 10.1042/0264-6021:3510817, 1221424, 11042139.
35. Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tao Q, Szallasi A, Razdan RK, Martin BR. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol 2000, 406:363-374. 10.1016/S0014-2999(00)00687-7, 11040343.
36. Committee on Animal Research of Kyoto University Faculty of Medicine Guidelines for Animal Experiments of Kyoto University Faculty of Medicine. (Japanese), Committee on Animal Research of Kyoto University Faculty of Medicine., http://www.kyoto-u.ac.jp/uni_int/kitei/reiki_honbun/aw00211691.html
37. Romero J, de Miguel R, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 1995, 694:223-232. 10.1016/0006-8993(95)00835-E, 8974649.
38. Kim KM, Kawada T, Ishihara K, Inoue K, Fushiki T. Inhibition by a capsaicin antagonist (capsazepine) of capsaicin-induced swimming capacity increase in mice. Biosci Biotechnol Biochem 1998, 62:2444-2445. 10.1271/bbb.62.2444, 9972272.
39. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem 2007, 14:63-74. 10.1101/lm.439007, 1828281,1828281, 17202425.
40. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 1997, 283:1138-1143.
41. Costa B, Giagnoni G, Colleoni M. Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berl) 2000, 149:121-128.
42. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
43. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E, Janowsky DS, Kling MA. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 1999, 142:193-199.
44. Vazquez-Palacios G, Bonilla-Jaime H, Velazquez-Moctezuma J. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine. Pharmacol Biochem Behav 2004, 78:165-169. 10.1016/j.pbb.2004.03.002, 15159146.
45. Andreasen JT, Redrobe JP. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 2009, 20:286-295. 10.1097/FBP.0b013e32832c713e, 19404193.
46. Morse DE. Neuroendocrine responses to nicotine and stress: enhancement of peripheral stress responses by the administration of nicotine. Psychopharmacology (Berl) 1989, 98:539-543.
47. Sun B, Sterling CR, Tank AW. Chronic nicotine treatment leads to sustained stimulation of tyrosine hydroxylase gene transcription rate in rat adrenal medulla. J Pharmacol Exp Ther 2003, 304:575-588. 10.1124/jpet.102.043596, 12538809.
48. Renard CE, Dailly E, David DJ, Hascoet M, Bourin M. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 2003, 17:449-455. 10.1046/j.1472-8206.2003.00160.x, 12914547.
49. Solich J, Pałach P, Budziszewska B, Dziedzicka-Wasylewska M. Effect of two behavioral tests on corticosterone level in plasma of mice lacking the noradrenaline transporter. Pharmacol Rep 2008, 60:1008-1013.
50. Marsch R, Foeller E, Rammes G, Bunck M, Kossl M, Holsboer F, Zieglgansberger W, Landgraf R, Lutz B, Wotjak CT. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007, 27:832-839. 10.1523/JNEUROSCI.3303-06.2007, 17251423.
51. Aguiar DC, Terzian AL, Guimarães FS, Moreira FA. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 2009, 205:217-225.
52. Bianchi BR, Lee CH, Jarvis MF, El Kouhen R, Moreland RB, Faltynek CR, Puttfarcken PS. Modulation of human TRPV1 receptor activity by extracellular protons and host cell expression system. Eur J Pharmacol 2006, 537:20-30. 10.1016/j.ejphar.2006.03.003, 16630609.
53. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005, 102:18620-18625. 10.1073/pnas.0509591102, 1317988, 16352709.
54. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15:593-599. 10.1016/j.euroneuro.2005.03.003, 15916883.
55. Mannucci C, Navarra M, Pieratti A, Russo GA, Caputi AP, Calapai G. Interactions Between Endocannabinoid and Serotonergic Systems in Mood Disorders Caused by Nicotine Withdrawal. Nicotine Tob Res 2011, 13:239-247. 10.1093/ntr/ntq242, 21324836.
56. Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711. 10.1523/JNEUROSCI.1636-07.2007, 17959812.
57. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 1999, 262:275-284. 10.1006/bbrc.1999.1105, 10448105.
58. de Lago E, Urbani P, Ramos JA, Di Marzo V, Fernández-Ruiz J. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Res 2005, 1050:210-216. 10.1016/j.brainres.2005.05.024, 15975564.
59. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824. 10.1038/39807, 9349813.